The figures are stark: half of us will be diagnosed with cancer in our lifetime. Despite decades of research, chemotherapy and radiation remain front-line treatments. These options often kill healthy and diseased cells indiscriminately which causes severe side effects. Worst of all, these conventional treatments may not successfully kill all cancer cells, leading to resistance and relapse in patients. There is a pressing need for smarter therapies that selectively target and kill cancer cells. This is something that, unfortunately, conventional drug discovery methods have struggled to deliver.
LabGenius has pioneered the development of a smart robotic platform capable of designing, conducting and, critically, learning from its own experiments. To achieve this, LabGenius has established a state-of-the-art protein engineering facility in London. Here, highly automated closed-loop experimentation has been combined with machine learning (ML) to discover a new generation of smarter therapies capable of selectively targeting and killing diseased cells.
© The content on this page is provided by the profiled company, and remains their copyright.
